

115TH CONGRESS  
2D SESSION

# H. R. 5353

---

IN THE SENATE OF THE UNITED STATES

JUNE 13, 2018

Received; read twice and referred to the Committee on Health, Education,  
Labor, and Pensions

---

## AN ACT

To amend the Public Health Service Act to reauthorize and expand a program of surveillance and education, carried out by the Centers for Disease Control and Prevention, regarding infections associated with injection drug use.

1       *Be it enacted by the Senate and House of Representa-*  
2       *tives of the United States of America in Congress assembled,*

1 **SECTION 1. SHORT TITLE.**

2 This Act may be cited as the “Eliminating Opioid Re-  
3 lated Infectious Diseases Act of 2018”.

4 **SEC. 2. REAUTHORIZATION AND EXPANSION OF PROGRAM**  
5 **OF SURVEILLANCE AND EDUCATION RE-**  
6 **GARDING INFECTIONS ASSOCIATED WITH IL-**  
7 **LICIT DRUG USE AND OTHER RISK FACTORS.**

8 Section 317N of the Public Health Service Act (42  
9 U.S.C. 247b–15) is amended to read as follows:

10 **“SEC. 317N. SURVEILLANCE AND EDUCATION REGARDING**  
11 **INFECTIONS ASSOCIATED WITH ILLICIT**  
12 **DRUG USE AND OTHER RISK FACTORS.**

13 “(a) IN GENERAL.—The Secretary may (directly and  
14 through grants to public and nonprofit private entities)  
15 provide for programs for the following:

16 “(1) To cooperate with the States and Indian  
17 tribes in implementing or maintaining a surveillance  
18 system to determine the incidence of infections com-  
19 monly associated with illicit drug use, including in-  
20 fections commonly associated with injection drug use  
21 such as viral hepatitis, human immunodeficiency  
22 virus, and infective endocarditis, and to assist the  
23 States in determining the prevalence of such infec-  
24 tions, which may include the reporting of cases of  
25 such infections.

1           “(2) To identify, counsel, and offer testing to  
2 individuals who are at risk of infections as a result  
3 of injection drug use, receiving blood transfusions  
4 prior to July 1992, or other risk factors.

5           “(3) To provide appropriate referrals for coun-  
6 seling, testing, and medical treatment of individuals  
7 identified under paragraph (2) and to ensure, to the  
8 extent practicable, the provision of appropriate fol-  
9 low-up services.

10           “(4) To develop and disseminate public infor-  
11 mation and education programs for the detection  
12 and control of infections described in paragraph (1),  
13 with priority given to high-risk populations as deter-  
14 mined by the Secretary.

15           “(5) To improve the education, training, and  
16 skills of health professionals in the detection and  
17 control of infections and the coordination of treat-  
18 ment of addiction and infectious diseases described  
19 in paragraph (1), with priority given to substance  
20 use disorder treatment providers, pediatricians and  
21 other primary care providers, obstetrician-gyne-  
22 cologists, infectious diseases clinicians, and HIV cli-  
23 nicians.

24           “(b) LABORATORY PROCEDURES.—The Secretary  
25 may (directly or through grants to public and nonprofit

1 private entities) carry out programs to provide for im-  
2 provements in the quality of clinical-laboratory procedures  
3 regarding infections described in subsection (a)(1).

4 “(c) DEFINITIONS.—In this section:

5 “(1) The term ‘Indian tribe’ has the meaning  
6 given that term in section 4 of the Indian Self-De-  
7 termination and Education Assistance Act.

8 “(2) The term ‘injection drug use’ means—

9 “(A) intravenous administration of a sub-  
10 stance in schedule I under section 202 of the  
11 Controlled Substances Act;

12 “(B) intravenous administration of a sub-  
13 stance in schedule II, III, IV, or V under sec-  
14 tion 202 of the Controlled Substances Act that  
15 has not been approved for intravenous use  
16 under—

17 “(i) section 505 of the Federal Food,  
18 Drug and Cosmetic Act; or

19 “(ii) section 351 of the Public Health  
20 Service Act; or

21 “(C) intravenous administration of a sub-  
22 stance in schedule II, III, IV, or V under sec-  
23 tion 202 of the Controlled Substances Act that  
24 has not been prescribed to the person using the  
25 substance.

1       “(d) AUTHORIZATION OF APPROPRIATIONS.—For the  
2 purpose of carrying out this section, there are authorized  
3 to be appropriated \$40,000,000 for each of the fiscal years  
4 2019 through 2023.”.

Passed the House of Representatives June 12, 2018.

Attest:

KAREN L. HAAS,

*Clerk.*